Immunogenetics of peripheral arteriopathies
Related Experiment Video
Updated: Oct 8, 2026

Mouse Models for Graft Arteriosclerosis
Published on: May 14, 2013
1Department of Histocompatibility and Immunogenetics, All India Institute of Medical Sciences, New Delhi. narin98@hotmail.com
Abstract:
Takayasu's arteritis (TA) and thrombangiitis obliterans (Buerger's disease) are idiopathic, inflammatory arteriopathies with strong indications for the involvement of autoimmunity and host genetic factors in their immunopathogenesis. The exact etiology of these arteriopathies still remains unknown even after almost nine decades of their description. A series of immunogenetic studies conducted worldwide seeking to define genetic factors in governing immune response in these diseases have yielded conflicting results on the involvement of HLA molecules. While an association of HLA-B5 or its molecular subtypes with Takayasu's arteriitis has been emphasized in patients from Japan, Korea and India, no such association has been reported in Mexican and North American patients. On the other hand, a limited data is available on the association of HLA antigens with Buerger's disease. In this article, we provide an overview of the immunogenetics of Buerger's disease and Takayasu's arteriitis in the context of studies in North Indian patients and those in other ethnic groups. Our studies indicate a positive association of Takayasu's arteriitis with the HLA-B5 molecule with no preferential association with its two major subtypes. In Buerger's disease, we have observed a strong positive association with HLA-DRB1*1501 consistent with the findings in Japanese patients. These results suggest an important role of HLA linked factors in governing susceptibility to both arteriopathies.
Related Concept Videos
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease I: Introduction
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Peripheral Artery Disease III: Interprofessional Care
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease I: Introduction